

# AM679

**Catalog No: tcsc0935**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1206880-66-1

**Formula:**

$C_{40}H_{44}N_4O_5S$

**Pathway:**

Immunology/Inflammation

**Target:**

FLAP

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

692.87

## Product Description

AM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively.


IC50 value: 2.2 nM/0.6 nM/154 nM (FLAP binding/hLA/hWB) [1]

Target: FLAP

in vitro: AM679 showed excellent in vitro inhibition against FLAP. AM679 has an excellent hWB IC50 potency of 154 nM. AM679 showed an improved CYP inhibition profile (IC50 3A4 = 16.7 nM, 2C9 = 3.7 nM, 2D6 >30 nM), no time dependent inhibition against CYP3A4 (0.003 min<sup>-1</sup> vs 0.057 min<sup>-1</sup> for troleandomycin control 10 μM) and no CYP3A4 induction.

in vivo: AM679 was profiled in a rodent bronchoalveolar lavage (BAL) model to measure its ability to inhibit production of

leukotrienes in vivo. Oral administration of 39 (10 mg/kg as the sodium carboxylate salt) 4 h prior to ionophore challenge reduced LTB4 and CysLT levels in the rodent lung lavage fluid by 98% and 87%, respectively, with corresponding average rodent plasma levels of 605 nM (3 h post dose, rat blood LTB4 IC50 = 125 nM).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!